Neo-NTP-CRT for Locally Advanced ESCC
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
- Status
- TERMINATED
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- Status
- RECRUITING
- Phase
- PHASE2
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Brazilian Lung Immunotherapy Study
- Status
- COMPLETED
- Phase
- PHASE2
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
- Status
- COMPLETED
- Phase
- N/A
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
- Status
- RECRUITING
- Phase
- PHASE2
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2